GGHC
NVO

Gilder Gagnon Howe & Co’s Novo Nordisk NVO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-211,510
Closed -$14.3M – 255
2022
Q4 		$14.3M Sell
211,510
-792,920
-79% -$46.5M 0.27% 91
2022
Q3 		$50M Buy
+1,004,430
New +$53.8M 0.87% 34

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Gilder Gagnon Howe & Co's NVO Position: Q1 2023 in Review

Gilder Gagnon Howe & Co sold out of Novo Nordisk (NVO) in Q1 2023, closing a stake of 211,510 shares — an estimated $14.3M sold.

Gilder Gagnon Howe & Co first reported a position in NVO in Q3 2022 and held it in 2 quarters. The position peaked at $50M in Q3 2022. 1,146 funds tracked by Wall St. Rank hold NVO as of Q1 2023.

  • Gilder Gagnon Howe & Co reported no remaining Novo Nordisk position as of Q1 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 211,510 Novo Nordisk shares in Q1 2023, an estimated $14.3M.
  • Gilder Gagnon Howe & Co first reported a position in Novo Nordisk in Q3 2022 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Novo Nordisk position peaked at $50M in Q3 2022.
  • 1,146 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2023, filed 15 May 2023.